China's rapid development of biological drugs, three sub-sectors into research and development hot spots

At present, in the global pharmaceutical market, biopharmaceuticals have become one of the sub-areas with rapid development momentum and broad prospects for development, and the market growth rate has remained above 5% in recent years.
this, and while the biopharmace idly drug market is still in its infancy, it is also showing strong growth potential.
, China's biopharmaceutical market reached 262.2 billion yuan in 2018, accounting for about 17.1% of the overall pharmaceutical market, according to the data.
With the growth of the patient population, the improvement of affordability and the expansion of health insurance coverage, the industry expects the size of China's biopharmaceons market to further expand to RMB641.2 billion by 2023, with a compound annual growth rate of 19.6% over the same period.
note that as of September 23, 2014, there were 227 new drugs approved in China, 64 of which were biological.
analysis of these biopharmaceonces, it is found that there are three major sub-sectors are currently the hot spots in the field of bio-innovative drugs.
expected that in the future, with the various drugs in these areas have been listed, the domestic biopharmaceonceon market will enter an outbreak period.
Recombinant protein drug recombinant protein drug refers to the use of gene recombinant technology, to obtain a recombinant vector connected to a gene fragment that can be translated into the purpose protein, and then transferred to the host cell that can express the purpose protein to express a specific recombinant protein molecule, can be used to compensate for the body due to congenital genetic defects or the absence of the corresponding functional proteins in the body.
current recombinant protein drugs mainly contain peptide hormones, cytokines, recombinant enzymes and other sub-areas.
widely used in the treatment of various major diseases, and the birth of a lot of heavy drugs, genetic engineering technology used in the pharmaceutical industry.
present, China's recombinant protein drug industry's main enterprises are Changchun High-tech, Stone Pharmaceutical Group, Tonghua Dongbao, Shenyang Sansheng Pharmaceuticals, Ha Pharmaceuticals Group, Kain Technology and so on.
Although the product range of recombinant protein drugs and the overall development of product innovation in China are not as good as between imported drugs, the price of recombinant protein drugs in China is low and has a strong price competitive advantage.
the support of future national policies, China's recombinant protein drug industry will be further developed, and the domestic alternative space in the sub-sectors will continue to expand.
vaccine drugs, the domestic vaccine market is usually divided into two categories: one vaccine and two vaccines.
type of vaccine refers to the vaccine used by the government to provide citizens with emergency or mass vaccination free of charge.
class II vaccines are other vaccines that are self-funded by citizens and are voluntarily vaccinated.
, a class of vaccines accounts for about 80% of the overall vaccine market.
past, China's first-class vaccine market is mainly produced and supplied by the six major domestic biological products research institutes, its share of the first-class vaccine market nearly 90%.
, but with some of the second-class vaccines included in the scope of a class of vaccines, it is expected that in the future private enterprises and foreign-funded enterprises will further seize the beach a class of vaccine market.
2008, China's vaccine market sales have exceeded 8 billion yuan, in 2018 the market size of 27.6 billion yuan.
industry believes that this trend is expected to reach 100.9 billion yuan by 2030.
but it is worth noting that as the market expands, competition among companies will become more intense.
antibody drugs domestic antibody drugs started late, but with the related areas of disease incidence and mortality increased year by year, the domestic demand for antibody drugs is huge.
, the antibody drug market is mainly dominated by tumors, autoimmune two major areas accounted for the share.
But with the deepening understanding of disease and the evolution of antibody technology, antibody drugs are slowly penetrating in areas other than cardiovascular, neurological diseases, gyro, infections and neurological diseases that are not traditional, or will become a new direction in the development of antibody drugs.
According to the data, as of August 2019, China has become a country with a large number of antibody drugs in research, there have been more than 200 antibody drugs approved clinical trial applications, some products have completed Phase III clinical trials and submitted a listing registration application.
At present, the main hot targets of antibody drug research include PD-1/PD-L1, TNF-α, VEGF, HER-2, CD20, EGFR, etc.